Malcolm McColl
Directeur Général chez Viralytics Ltd.
Postes actifs de Malcolm McColl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Viralytics Ltd. | Directeur Général | 01/01/2013 | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Directeur Général | 01/01/2019 | - |
| Président | 04/08/2021 | - | |
| Fondateur | 01/01/2019 | - |
Historique de carrière de Malcolm McColl
Anciens postes connus de Malcolm McColl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Mayne Pharma, Inc.
 Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Corporate Officer/Principal | 01/01/2007 | 01/01/2010 |
| VIRALYTICS LTD. | Directeur/Membre du Conseil | 21/01/2013 | - |
| Directeur Général | 21/01/2013 | - | |
| Investor Relations Contact | - | - | |
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 04/01/2011 | - |
Formation de Malcolm McColl
| Melbourne Business School | Masters Business Admin |
| University of Melbourne | Undergraduate Degree |
Statistiques
Internationale
| Australie | 7 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| STARPHARMA HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
Mayne Pharma, Inc.
Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Health Technology |
| Viralytics Ltd. | |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
- Bourse
- Insiders
- Malcolm McColl
- Expérience
